Abstract:A combination administration of chemical agents was highlighted to treat tumors. Recently, tumor cell has been found to be different from normal cell in metabolic manner. Most of cancer cells prefer aerobic glycolysis to mitochondrial oxidative phosphorylation (OXPHOS) to satisfy energy and biomass synthesis requirement to survive, grow and proliferate, which provides novel and potential therapeutic targets for chemotherapy. Here, 2-deoxy-d-glucose (2-DG), a potent inhibitor of glucose metabolism, was used to inhibit glycolysis of tumor cells; α-tocopheryl succinate (α-TOS), a water-insoluble vitamin E derivative, was chosen to suppress OXPHOS. Our data demonstrated that the combination treatment of 2-DG and α-TOS could significantly promote the anti-tumor efficiency in vitro compared with administration of the single drug. In order to maximize therapeutic activity and minimize negative side effects, a co-delivery nanocarrier targeting folate receptor (FR) was developed to encapsulate 2-DG and α-TOS simultaneously based on our previous work. Transmission electron microscope, dynamic light scattering method and UV-visible spectrophotometers were used to investigate morphology, size distribution and loading efficiency of the α-TOS-2-DG-loaded and FR-targeted nanoparticles (TDF NPs). The TDF NPs were found to possess a layer-by-layer shape, and the dynamic size was <100 nm. The final encapsulation efficiencies of α-TOS and 2-DG in TDF NPs were 94.3%±1.3% and 61.7%±7.7% with respect to drug-loading capacities of 8.9%±0.8% and 13.2%±2.6%, respectively. Almost no α-TOS release was found within 80 h, and release of 2-DG was sustained and slow within 72 h. The results of FR binding assay and fluorescence biodistribution revealed that TDF NPs could target FR highly expressed on tumor cell in vitro and in vivo. Further, in vivo anti-tumor experiments showed that TDF NPs had an improved biological function with less toxicity. Thus, our work indicates that the co-delivery TDF NPs have a great potential in tumor therapy.

Targeted Delivery of Antisense Oligodeoxynucleotides to Folate Receptor-Overexpressing Tumor Cells

Reversion of Multidrug Resistance by Tumor Targeted Delivery of Antisense Oligodeoxynucleotides in Hydroxypropyl-Chitosan Nanoparticles.

Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor α

Enhanced lysosome escape mediated by 1,2-dicarboxylic-cyclohexene anhydride-modified poly-L-lysine dendrimer as a gene delivery system

Co-delivery of Doxorubicin and Shrna of Beclin1 by Folate Receptor Targeted Pullulan-Based Multifunctional Nanomicelles for Combinational Cancer Therapy

Co-delivery Nanocarriers Targeting Folate Receptor and Encapsulating 2-Deoxyglucose and Α-Tocopheryl Succinate Enhance Anti-Tumor Effect in Vivo.

Enhanced Apoptosis of Ovarian Cancer Cells Via Nanocarrier-Mediated Codelivery of Sirna and Doxorubicin

Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment

Codelivery of DOX and Sirna by Folate-Biotin-quaternized Starch Nanoparticles for Promoting Synergistic Suppression of Human Lung Cancer Cells

Antiangiogenesis and Damaging Blood Flow by Antisense Vascular Endothelial Growth Factor Oligodeoxynucleotides to Suppress Lung Cancers

Folate-Functionalized Magnetic-Mesoporous Silica Nanoparticles for Drug/Gene Codelivery to Potentiate the Antitumor Efficacy.

Dually Active Targeting Nanomedicines Based on a Direct Conjugate of Two Purely Natural Ligands for Potent Chemotherapy of Ovarian Tumors

Folic Acid-Conjugated Fluorescent Polymer for Up-Regulation Folate Receptor Expression Study Via Targeted Imaging of Tumor Cells.

Folate and TAT Peptide Co-Modified Liposomes Exhibit Receptor-Dependent Highly Efficient Intracellular Transport of Payload in Vitro and in Vivo

Enhanced Intracellular Protein Transduction By Sequence Defined Tetra-Oleoyl Oligoaminoamides Targeted For Cancer Therapy

In Vivo Delivery of Antisense Morf Oligomer by Morf/Carrier Streptavidin Nanoparticles

Enhanced antisense oligonucleotide delivery using cationic liposomes incorporating fatty acid-modified polyethylenimine.

Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.

Lipopolyplex-Mediated Co-Delivery of Doxorubicin and FAK siRNA to Enhance Therapeutic Efficiency of Treating Colorectal Cancer

Targeted Delivery of Therapeutic Oligonucleotides to Pulmonary Circulation.

Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.